Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing
The U.K. has suspended new prescriptions for Tavneos (Avacopan Vifor) due to data integrity concerns, according to the MHRA. Amgen, which owns Tavneos in the U.S., disagrees, citing real-world studies supporting the drug's effectiveness. The MHRA will revoke the drug's authorization by March 1, 2027. Similar actions have been taken by the FDA and EMA.
How this was made
The 30-second read
Why it matters
Regulatory actions across three major regions create immediate downside risk for Amgen's stock and raise questions about the drug's future pipeline.
Market read
First‑report regulatory withdrawal for a high‑profile rare‑disease therapy, likely to move Amgen stock and affect biotech sector sentiment.
What to watch
Potential insurance reimbursements and off‑label use in other markets could cushion revenue loss.
Background
The article reports the first public announcement that the UK MHRA has suspended new patient use of Tavneos and that the EMA has withdrawn its marketing authorization, following earlier FDA concerns.
Ticker impact
UK regulator MHRA suspends Tavneos (Avacopan Vifor) for new patients and EMA withdraws its EU authorization, directly affecting Amgen's marketed drug.
Potential short-term decline of 3‑5% as investors reassess revenue exposure.
Amgen's flagship rare‑disease drug faces market removal in major regions, reducing future sales and raising litigation risk.
Market effects
Biotech and rare‑disease sector may see heightened regulatory scrutiny.
UK and EU markets could see broader sell‑offs in similar specialty drug stocks.
Amgen's global valuation may be adjusted as investors price in lost UK/EU revenue.
Counterpoint
Amgen may retain strong US sales and could launch a reformulated version, limiting long‑term damage.
Key entities
- CompanyAmgen
Owner of Tavneos in the United States.
- RegulatorMHRA
UK Medicines and Healthcare products Regulatory Agency.
- RegulatorEMA
European Medicines Agency.
